8-K Announcements
6Material company update
Mar 30, 2026·SEC
Material company update
Mar 18, 2026·SEC
Material company update
Jan 26, 2026·SEC
4D Molecular Therapeutics, Inc.(FDMT)Earnings, Financials & Key Ratios
FDMT•NASDAQ
$10.42
$600M mkt cap·Price updated May 6, 2026
About4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.Show more
- Revenue$85M+230194.6%
- EBITDA-$152M+16.1%
- Net Income-$140M+12.9%
- EPS (Diluted)-2.42+18.8%
- Gross Margin91.05%-8.9%
- EBITDA Margin-178.29%+100.0%
- Operating Margin-187.24%+100.0%
- Net Margin-164.43%+100.0%
- ROE-27.57%+29.9%
- ROIC-28.07%+54.3%
- Debt/Equity0.04-12.1%
FDMT Key Insights
4D Molecular Therapeutics, Inc. (FDMT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 44.3%
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FDMT Price & Volume
4D Molecular Therapeutics, Inc. (FDMT) stock price & volume — 10-year historical chart
Loading chart...
FDMT Growth Metrics
4D Molecular Therapeutics, Inc. (FDMT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years44.32%
3 Years200.86%
TTM230194.59%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM12.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.77%
Return on Capital
10 Years-39.81%
5 Years-35.07%
3 Years-38.06%
Last Year-30.28%
FDMT Recent Earnings
4D Molecular Therapeutics, Inc. (FDMT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
Mar 18, 2026EPS
$0.43
Est $0.53
+181.1%
Revenue
$85M
Est $27M
+215.2%
Q4 2025
Nov 10, 2025EPS
$1.01
Est $1.02
+1.0%
Revenue
$90,000
Est $31M
-99.7%
Q3 2025
Aug 11, 2025EPS
$0.98
Est $0.88
-11.4%
Revenue
$15,000
Est $4,670
+221.2%
Q2 2025
May 8, 2025EPS
$0.86
Est $0.84
-2.4%
Revenue
$14,000
Est $537,500
-97.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 18, 2026 | $0.43vs $0.53+181.1% | $85Mvs $27M+215.2% |
| Q4 2025 | Nov 10, 2025 | $1.01vs $1.02+1.0% | $90,000vs $31M-99.7% |
| Q3 2025 | Aug 11, 2025 | $0.98vs $0.88-11.4% | $15,000vs $4,670+221.2% |
| Q2 2025 | May 8, 2025 | $0.86vs $0.84-2.4% | $14,000vs $537,500-97.4% |
Based on last 12 quarters of dataView full earnings history →
FDMT Peer Comparison
4D Molecular Therapeutics, Inc. (FDMT) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCGN | 492.54M | 1.46 | -6.33 | 8.83% | -15.37% | -26.26% | ||
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 QURE | 1.41B | 22.82 | -6.60 | -40.64% | -11.54% | -145.81% | 2.70 | |
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 |
Compare FDMT vs Peers
4D Molecular Therapeutics, Inc. (FDMT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FDMT Income Statement
4D Molecular Therapeutics, Inc. (FDMT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.79M | 14.13M | 6.99M | 13.61M | 18.04M | 3.13M | 20.72M | 37K | 85.21M |
| Revenue Growth % | - | 144.04% | -50.56% | 94.85% | 32.52% | -82.65% | 562.29% | -99.82% | 230194.59% |
| Cost of Goods Sold | 13.57M | 18.36M | 38.72M | 53.04M | 61.36M | 80.25M | 97.1M | 0 | 7.63M |
| COGS % of Revenue | 234.42% | 129.95% | 554.22% | 389.64% | 340.17% | 2564.81% | 468.54% | - | 8.95% |
| Gross Profit | -7.78M▲ 0% | -4.23M▲ 45.6% | -31.73M▼ 649.8% | -39.43M▼ 24.2% | -43.32M▼ 9.9% | -77.12M▼ 78.0% | -76.37M▲ 1.0% | 37K▲ 100.0% | 77.58M▲ 209586.5% |
| Gross Margin % | -134.42% | -29.95% | -454.22% | -289.64% | -240.17% | -2464.81% | -368.54% | 100% | 91.05% |
| Gross Profit Growth % | - | 45.63% | -649.81% | -24.25% | -9.88% | -78.03% | 0.97% | 100.05% | 209586.49% |
| Operating Expenses | 17.06M | 24.53M | 19.03M | 17.24M | 28.01M | 32.91M | 36.49M | 187.88M | 237.13M |
| OpEx % of Revenue | 294.68% | 173.6% | 272.43% | 126.64% | 155.29% | 1051.71% | 176.1% | 507778.38% | 278.29% |
| Selling, General & Admin | 3.49M | 6.17M | 13.89M | 17.24M | 28.01M | 32.91M | 36.49M | 46.58M | 49.06M |
| SG&A % of Revenue | 60.26% | 43.64% | 198.9% | 126.64% | 155.29% | 1051.71% | 176.1% | 125889.19% | 57.58% |
| Research & Development | 13.57M | 18.36M | 43.85M | 53.04M | 61.36M | 80.25M | 97.1M | 141.3M | 195.7M |
| R&D % of Revenue | 234.42% | 129.95% | 627.76% | 389.64% | 340.17% | 2564.81% | 468.54% | 381889.19% | 229.67% |
| Other Operating Expenses | -40K | -2K | -38.72M | -53.04M | -61.36M | -80.25M | -97.1M | 0 | -7.63M |
| Operating Income | -11.27M▲ 0% | -10.4M▲ 7.7% | -50.76M▼ 388.2% | -56.66M▼ 11.6% | -71.33M▼ 25.9% | -110.03M▼ 54.3% | -112.87M▼ 2.6% | -187.84M▼ 66.4% | -159.55M▲ 15.1% |
| Operating Margin % | -194.68% | -73.6% | -726.65% | -416.28% | -395.46% | -3516.52% | -544.65% | -507678.38% | -187.24% |
| Operating Income Growth % | - | 7.74% | -388.16% | -11.62% | -25.89% | -54.25% | -2.58% | -66.43% | 15.06% |
| EBITDA | -10.65M | -9.7M | -49.76M | -55.22M | -69.81M | -107.63M | -108.66M | -181.14M | -151.92M |
| EBITDA Margin % | -183.87% | -68.66% | -712.28% | -405.68% | -387.02% | -3439.73% | -524.36% | -489556.76% | -178.29% |
| EBITDA Growth % | - | 8.87% | -412.88% | -10.97% | -26.42% | -54.17% | -0.96% | -66.7% | 16.13% |
| D&A (Non-Cash Add-back) | 626K | 697K | 1M | 1.44M | 1.52M | 2.4M | 4.2M | 6.71M | 7.63M |
| EBIT | -11.27M | -10.4M | -45.63M | -56.66M | -71.33M | -110.03M | -112.87M | -187.84M | -159.55M |
| Net Interest Income | 89K | 850K | 1.5M | 152K | 137K | 2.57M | 12.21M | 27.05M | 19.48M |
| Interest Income | 89K | 850K | 1.5M | 152K | 137K | 2.57M | 12.21M | 27.05M | 19.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 49K | 848K | 1.46M | -29K | 16K | 2.54M | 12.03M | 26.97M | 19.44M |
| Pretax Income | -11.22M▲ 0% | -9.55M▲ 14.9% | -49.31M▼ 416.2% | -56.69M▼ 15.0% | -71.32M▼ 25.8% | -107.49M▼ 50.7% | -100.84M▲ 6.2% | -160.87M▼ 59.5% | -140.11M▲ 12.9% |
| Pretax Margin % | -193.83% | -67.59% | -705.78% | -416.49% | -395.37% | -3435.41% | -486.59% | -434778.38% | -164.43% |
| Income Tax | -89K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.79% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -11.22M▲ 0% | -9.55M▲ 14.9% | -49.31M▼ 416.2% | -56.69M▼ 15.0% | -71.32M▼ 25.8% | -107.49M▼ 50.7% | -100.84M▲ 6.2% | -160.87M▼ 59.5% | -140.11M▲ 12.9% |
| Net Margin % | -193.83% | -67.59% | -705.78% | -416.49% | -395.37% | -3435.41% | -486.59% | -434778.38% | -164.43% |
| Net Income Growth % | - | 14.9% | -416.24% | -14.98% | -25.8% | -50.73% | 6.19% | -59.53% | 12.9% |
| Net Income (Continuing) | -11.22M | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M | -140.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.76▲ 0% | -0.76▲ 0.0% | -2.00▼ 163.2% | -2.12▼ 6.0% | -2.46▼ 16.0% | -3.12▼ 26.8% | -2.58▲ 17.3% | -2.98▼ 15.5% | -2.42▲ 18.8% |
| EPS Growth % | - | 0% | -163.16% | -6% | -16.04% | -26.83% | 17.31% | -15.5% | 18.79% |
| EPS (Basic) | -0.76 | -0.76 | -2.00 | -2.12 | -2.46 | -3.12 | -2.58 | -2.98 | -2.42 |
| Diluted Shares Outstanding | 14.84M | 12.52M | 26.49M | 26.68M | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
| Basic Shares Outstanding | 14.84M | 12.52M | 26.49M | 26.68M | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
FDMT Balance Sheet
4D Molecular Therapeutics, Inc. (FDMT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 24.5M | 94.07M | 52.51M | 282.66M | 256.28M | 220.51M | 296.59M | 434.93M | 413.13M |
| Cash & Short-Term Investments | 23.85M | 91.76M | 49.65M | 276.73M | 247.78M | 213.55M | 288.23M | 424.88M | 402.65M |
| Cash Only | 23.85M | 91.76M | 49.65M | 276.73M | 153M | 52.35M | 249.11M | 149.34M | 60.24M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 94.78M | 161.2M | 39.12M | 275.54M | 342.41M |
| Accounts Receivable | 321K | 1.12M | 978K | 1.49M | 47K | 700K | 0 | 0 | 0 |
| Days Sales Outstanding | 20.24 | 29.03 | 51.1 | 39.85 | 0.95 | 81.66 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 4.44M | 0 | 6.26M | 8.36M | 10.05M | 10.48M |
| Total Non-Current Assets | 2.82M | 2.9M | 5.73M | 5.67M | 97.21M | 41.34M | 43.3M | 125.45M | 153.58M |
| Property, Plant & Equipment | 2.72M | 2.47M | 5.05M | 5.07M | 28.95M | 35.35M | 31.66M | 40.61M | 33.01M |
| Fixed Asset Turnover | 2.13x | 5.72x | 1.38x | 2.68x | 0.62x | 0.09x | 0.65x | 0.00x | 2.58x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 67.65M | 4.91M | 10.95M | 80.58M | 0 |
| Other Non-Current Assets | 105K | 429K | 677K | 602K | 602K | 1.08M | 684K | 4.26M | 120.57M |
| Total Assets | 27.32M▲ 0% | 96.97M▲ 254.9% | 58.23M▼ 39.9% | 288.33M▲ 395.1% | 353.49M▲ 22.6% | 261.85M▼ 25.9% | 339.89M▲ 29.8% | 560.38M▲ 64.9% | 566.71M▲ 1.1% |
| Asset Turnover | 0.21x | 0.15x | 0.12x | 0.05x | 0.05x | 0.01x | 0.06x | 0.00x | 0.15x |
| Asset Growth % | - | 254.94% | -39.95% | 395.12% | 22.6% | -25.92% | 29.81% | 64.87% | 1.13% |
| Total Current Liabilities | 5.91M | 8.05M | 12.96M | 16.74M | 16.34M | 15.73M | 18.95M | 29.15M | 43.98M |
| Accounts Payable | 460K | 954K | 1.74M | 1.79M | 4.76M | 3.32M | 3.52M | 4.39M | 11.16M |
| Days Payables Outstanding | 12.37 | 18.96 | 16.44 | 12.3 | 28.34 | 15.11 | 13.21 | - | 534.17 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.65M | 0 | 0 | 5.59M |
| Deferred Revenue (Current) | 4.38M | 4.91M | 5.86M | 6.59M | 2.6M | 884K | 273K | 257K | 360K |
| Other Current Liabilities | 279K | 0 | 0 | 0 | 0 | 3.18M | 3.87M | 0 | 26.87M |
| Current Ratio | 4.15x | 11.68x | 4.05x | 16.88x | 15.69x | 14.02x | 15.65x | 14.92x | 9.39x |
| Quick Ratio | 4.15x | 11.68x | 4.05x | 16.88x | 15.69x | 14.02x | 15.65x | 14.92x | 9.39x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 41M | 116.5M | 118.25M | 15.2M | 18.04M | 14.78M | 13.11M | 20.63M | 17.06M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.82M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 15.22M | 13.47M | 11.52M | 18.97M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 18.81M | 103.43M | 104.65M | 1.97M | 334K | 233K | 617K | 603K | 496K |
| Total Liabilities | 46.91M | 124.56M | 131.2M | 31.94M | 34.38M | 30.51M | 32.06M | 49.78M | 61.05M |
| Total Debt | 0 | 0 | 0 | 0 | 16.45M | 16.12M | 14.67M | 24.61M | 21.41M |
| Net Debt | -23.85M | -91.76M | -49.65M | -276.73M | -136.55M | -36.23M | -234.44M | -124.73M | -38.83M |
| Debt / Equity | - | - | - | - | 0.05x | 0.07x | 0.05x | 0.05x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | -19.59M▲ 0% | -27.59M▼ 40.8% | -72.97M▼ 164.5% | 256.39M▲ 451.4% | 319.11M▲ 24.5% | 231.34M▼ 27.5% | 307.83M▲ 33.1% | 510.61M▲ 65.9% | 505.66M▼ 1.0% |
| Equity Growth % | - | -40.82% | -164.51% | 451.36% | 24.46% | -27.5% | 33.07% | 65.87% | -0.97% |
| Book Value per Share | -1.32 | -2.20 | -2.75 | 9.61 | 11.51 | 7.15 | 7.87 | 9.47 | 8.73 |
| Total Shareholders' Equity | -19.59M | -27.59M | -72.97M | 256.39M | 319.11M | 231.34M | 307.83M | 510.61M | 505.66M |
| Common Stock | 1K | 1K | 1K | 3K | 3K | 3K | 4K | 5K | 6K |
| Retained Earnings | -20.48M | -30.03M | -79.03M | -135.68M | -207M | -314.49M | -415.33M | -576.2M | -716.3M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -18.51M | -102.98M | -102.98M | -288.33M | -423K | -1.2M | 16K | 229K | 727K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FDMT Cash Flow Statement
4D Molecular Therapeutics, Inc. (FDMT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 8.24M | -16.25M | -36.71M | -50.91M | -69.13M | -86.69M | -75.79M | -134.59M | -109.08M |
| Operating CF Margin % | 142.26% | -115.02% | -525.49% | -374% | -383.27% | -2770.37% | -365.74% | -363743.24% | -128.02% |
| Operating CF Growth % | - | -297.3% | -125.89% | -38.68% | -35.8% | -25.39% | 12.57% | -77.57% | 18.95% |
| Net Income | -11.22M | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M | -140.11M |
| Depreciation & Amortization | 626K | 697K | 1M | 1.44M | 3.02M | 3.88M | 5.75M | 6.71M | 7.63M |
| Stock-Based Compensation | 256K | 1.38M | 3.54M | 4.98M | 13.8M | 17.12M | 19.66M | 26.12M | 22.02M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 39K | 2K | 7.79M | 69K | 898K | 1.14M | -999K | -7.08M | -4.79M |
| Working Capital Changes | 18.54M | -8.78M | 259K | -712K | -15.53M | -1.34M | 630K | 537K | 6.17M |
| Change in Receivables | -320K | -803K | 146K | -508K | 1.44M | 47K | 0 | 0 | 0 |
| Change in Inventory | -53K | 175K | 0 | 0 | -4.54M | 0 | 0 | 0 | 0 |
| Change in Payables | -114K | 438K | 533K | 43K | 2.29M | -1.64M | 896K | 871K | 6.77M |
| Cash from Investing | 7.67M | -414K | -3.2M | -1M | -172.68M | -17.05M | 115.72M | -302.44M | -92.97M |
| Capital Expenditures | -573K | -414K | -3.2M | -1M | -9.11M | -11.54M | -2.77M | -3.79M | -536K |
| CapEx % of Revenue | 9.9% | 2.93% | 45.85% | 7.35% | 50.5% | 368.68% | 13.37% | 10232.43% | 0.63% |
| Acquisitions | 24K | 0 | 0 | 0 | 9.11M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 24K | 0 | 0 | 0 | -9.11M | 0 | 173.29M | 0 | 0 |
| Cash from Financing | 16K | 84.58M | -2.19M | 278.98M | 118.09M | 3.08M | 156.83M | 337.25M | 112.96M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 16K | 0 | -1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 84.58M | 0 | 857K | 3.79M | 0 | 8.49M | 5.84M | 0 |
| Net Change in Cash | 15.93M▲ 0% | 67.91M▲ 326.4% | -42.11M▼ 162.0% | 227.07M▲ 639.3% | -123.72M▼ 154.5% | -100.65M▲ 18.7% | 196.76M▲ 295.5% | -99.77M▼ 150.7% | -89.09M▲ 10.7% |
| Free Cash Flow | 7.66M▲ 0% | -16.67M▼ 317.5% | -39.91M▼ 139.5% | -51.91M▼ 30.1% | -78.24M▼ 50.7% | -98.22M▼ 25.5% | -78.56M▲ 20.0% | -138.37M▼ 76.1% | -109.08M▲ 21.2% |
| FCF Margin % | 132.37% | -117.95% | -571.34% | -381.35% | -433.77% | -3139.05% | -379.11% | -373975.68% | -128.02% |
| FCF Growth % | - | -317.46% | -139.49% | -30.05% | -50.73% | -25.53% | 20.01% | -76.13% | 21.17% |
| FCF per Share | 0.52 | -1.33 | -1.51 | -1.95 | -2.82 | -3.04 | -2.01 | -2.57 | -1.88 |
| FCF Conversion (FCF/Net Income) | -0.73x | 1.70x | 0.74x | 0.90x | 0.97x | 0.81x | 0.75x | 0.84x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FDMT Key Ratios
4D Molecular Therapeutics, Inc. (FDMT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -61.82% | -24.78% | -39.06% | -37.4% | -39.31% | -27.57% |
| Return on Invested Capital (ROIC) | - | - | - | - | -65.96% | -43.7% | -63.05% | -61.35% | -28.07% |
| Gross Margin | -134.42% | -29.95% | -454.22% | -289.64% | -240.17% | -2464.81% | -368.54% | 100% | 91.05% |
| Net Margin | -193.83% | -67.59% | -705.78% | -416.49% | -395.37% | -3435.41% | -486.59% | -434778.38% | -164.43% |
| Debt / Equity | - | - | - | - | 0.05x | 0.07x | 0.05x | 0.05x | 0.04x |
| FCF Conversion | -0.73x | 1.70x | 0.74x | 0.90x | 0.97x | 0.81x | 0.75x | 0.84x | 0.78x |
| Revenue Growth | - | 144.04% | -50.56% | 94.85% | 32.52% | -82.65% | 562.29% | -99.82% | 230194.59% |
FDMT SEC Filings & Documents
4D Molecular Therapeutics, Inc. (FDMT) SEC filings — annual & quarterly reports (10-K, 10-Q)
FDMT Frequently Asked Questions
4D Molecular Therapeutics, Inc. (FDMT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
4D Molecular Therapeutics, Inc. (FDMT) reported $85.2M in revenue for fiscal year 2025. This represents a 1372% increase from $5.8M in 2017.
4D Molecular Therapeutics, Inc. (FDMT) grew revenue by 230194.6% over the past year. This is strong growth.
4D Molecular Therapeutics, Inc. (FDMT) reported a net loss of $140.1M for fiscal year 2025.
Dividend & Returns
4D Molecular Therapeutics, Inc. (FDMT) has a return on equity (ROE) of -27.6%. Negative ROE indicates the company is unprofitable.
4D Molecular Therapeutics, Inc. (FDMT) had negative free cash flow of $110.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More FDMT
4D Molecular Therapeutics, Inc. (FDMT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates